Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index; 46 of the 104 sources its claims cite were checked for support.

The progression of secondary diabetes: A review of modeling studies

Open access
Yang, Boya, Li, Jiaxu, Haller, Michael J., Schatz, Desmond A., Rong, Libin · 2022 · Frontiers in Endocrinology

Abstract

Mathematical modeling has provided quantitative information consistent with experimental data, greatly improving our understanding of the progression of type 1 and type 2 diabetes. However, diabetes is a complex metabolic disease and has been found to be involved in crosstalk interactions with diverse endocrine diseases. Mathematical models have also been developed to investigate the quantitative impact of various hormonal disorders on glucose imbalance, advancing the precision treatment for secondary diabetes. Here we review the models established for the study of dysglycemia induced by hormonal disorders, such as excessive glucocorticoids, epinephrine, and growth hormone. To investigate the influence of hyperthyroidism on the glucose regulatory system, we also propose a hyperthyroid-diabetes progression model. Model simulations indicate that timely thyroid treatment can halt the progression of hyperglycemia and prevent beta-cell failure. This highlights the diagnosis of hormonal disorders, together withblood sugar tests, as significant measures for the early diagnosis and treatment of diabetes. The work recapitulates updated biological research on the interactions between the glucose regulatory system and other endocrine axes. Further mathematical modeling of secondary diabetes is desired to promote the quantitative study of the disease and the development of individualized diabetic therapies.

Overview

CoChat Summary

TL;DR

This review summarizes mathematical models of secondary diabetes caused by excess glucocorticoids, epinephrine, and growth hormone, and proposes a new hyperthyroid-diabetes progression model. Simulations suggest timely anti-thyroid treatment can halt hyperglycemia and prevent beta-cell failure, whereas delayed treatment does not reverse diabetes.

Key findings

  • The paper reviews existing models for dysglycemia induced by glucocorticoids, epinephrine, and growth hormone, noting that models for secondary diabetes remain sparse compared with type 1 and type 2 diabetes models.
  • In the new hyperthyroid-diabetes model, a fast-progressing virtual patient’s glucose reached 122.5 mg/dl on day 507, was dragged down to 114.5 mg/dl in 63 days, then crossed the 125 mg/dl diabetes threshold after 1.7 years; complete beta-cell failure occurred when FT4 exceeded its set point by 124%.
  • A slowly progressing virtual patient reached FT4 20 pg/ml in about 18.5 years, 17 years later than the fast-progressing patient, and diabetes onset was postponed by 16.7 years; however, at FT4 24.1 pg/ml this patient was in late-stage diabetes while the fast-progressing patient had just crossed the diabetes threshold.
  • Timely anti-thyroid drug treatment starting after day 500 reduced FT4 by 5.2 pg/ml and glucose by 19.3 units in 10 days, with FT4 approaching 12.9 pg/ml and glucose regulated within normal range after day 1500; belated treatment starting on day 700 failed to reverse diabetes.

Methods

  • Narrative review of mathematical models for secondary diabetes induced by glucocorticoids, epinephrine, and growth hormone, plus formulation of a new hyperthyroid-diabetes progression model based on a previous generalized diabetes progression model.
  • The new model incorporates FT4 and TSH dynamics, a hyperthyroid factor \(X=|T3-U|/U\), influence functions \(p_i(X)\), and an anti-thyroid drug treatment term; parameters are listed in Table 1, with several adopted from prior work validated by Pima Indian data.
  • Simulations compare virtual patients with fast versus slow hyperthyroid progression and different anti-thyroid drug regimens; normal reference ranges used include FT4 7–18 pg/ml, TSH 0.4–4 mU/l, and FT4 set point \(U=12.5\) pg/mL.

Limitations

  • The paper states the hyperthyroid submodel includes only FT4 and TSH, omitting T3–TSH interaction, deiodinase activities, TSH effects on glucose regulation, and effects of excess thyroid hormones on insulin degradation for simplicity.
  • The paper states the model was not validated with individual measurements of blood glucose, insulin, FT4, and TSH, calling this a common predicament for models of interacting subsystems.
  • Evident from the text: the new model’s conclusions rest on deterministic simulations of virtual patients rather than clinical cohort data, and the authors note stochastic or statistical models would be closer to reality but more complex.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1070979

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The impact of diverse hormones on the glucose regulatory system. The detailed influences of a specific hormone on glucose regulation are described in text.
Figure 1 The impact of diverse hormones on the glucose regulatory system. The detailed influences of a specific hormone on glucose regulation are described in text.CC BY · PubMed Central
Figure 2 The effects of epinephrine on glucose regulation. Surgery induced metabolic stress, which causes the acute elevation of epinephrine, can significantly increase the rate of dysglycemia of hospitalized patients. The acute influence of epinephrine on the glucose regulation have been shown to be divergent from the impact of chronic infusion of low-dose epinephrine in vivo (30–33).
Figure 2 The effects of epinephrine on glucose regulation. Surgery induced metabolic stress, which causes the acute elevation of epinephrine, can significantly increase the rate of dysglycemia of hospitalized patients. The acute influence of epinephrine on the glucose regulation have been shown to be divergent from the impact of chronic infusion of low-dose epinephrine in vivo (30–33).CC BY · PubMed Central
Figure 3 The effects of GH on glucose regulation are intricate partially due to its indirect impacts via IGF-1, which has glucose-lowering functions analogous to insulin. Low-dose GH has been shown to benefit insulin sensitivity and glucose homeostasis due to increased circulating IGF-1, while long-term GH treatment in high doses impairs insulin sensitivity and exacerbates insulin resistance.
Figure 3 The effects of GH on glucose regulation are intricate partially due to its indirect impacts via IGF-1, which has glucose-lowering functions analogous to insulin. Low-dose GH has been shown to benefit insulin sensitivity and glucose homeostasis due to increased circulating IGF-1, while long-term GH treatment in high doses impairs insulin sensitivity and exacerbates insulin resistance.CC BY · PubMed Central
Figure 4 The HPT-axis negative feedback mechanism. The free T3 and T4 concentrations lower than their respective normal set point values lead to the secretion of TRH from the hypothalamus. The pituitary gland is subsequently promoted to produce and secrete TSH into the blood, which in turn stimulates the thyroid follicle cells to secrete T3 and T4. In contrast, when the plasma levels of free T3 and T4 are elevated beyond their normal range, the hypothalamus and pitutary gland respond by reducing the secretion of TRH and TSH, which slows down the production of T3 and T4.
Figure 4 The HPT-axis negative feedback mechanism. The free T3 and T4 concentrations lower than their respective normal set point values lead to the secretion of TRH from the hypothalamus. The pituitary gland is subsequently promoted to produce and secrete TSH into the blood, which in turn stimulates the thyroid follicle cells to secrete T3 and T4. In contrast, when the plasma levels of free T3 and T4 are elevated beyond their normal range, the hypothalamus and pitutary gland respond by reducing the secretion of TRH and TSH, which slows down the production of T3 and T4.CC BY · PubMed Central
Figure 5 Dynamics of glucose, insulin, and functional beta-cell mass level with fast progressing hyperthyroidism. (A-D) Time evolution of blood glucose concentration, plasma FT4 and TSH concentrations, insulin level, and functional betacellmass. The initial conditions of FT4 and TSH are set to be 12.5 pg/ml and 0.6 mU/l, respectively. The parametervalues are listed in Table 1 . We assume the FT4 synthesis factor for patient A to be a1(t)=6.9+30/(1+e^(6−0.01t)) . Withthe gradual elevation of FT4, the glucose level of this patient would reach 122.5 mg/dl on day 507. The glucose wouldbe dragged down slightly to 114.5 mg/dl in 63 days by improved insulin sensitivity. However, the glucose level wouldrise again thereafter subsequent to the continuous decline of insulin, which is caused by the damage of excessive thyroidhormones to beta-cells. With the gradual elevation of FT4 for 1.7 years, the glucose level of patient A would cross 125mg/dl, the threshold of overt diabetes. As the FT4 level further increases, a complete beta-cell failure occurs and drivespatient A to the late stage of diabetes.
Figure 5 Dynamics of glucose, insulin, and functional beta-cell mass level with fast progressing hyperthyroidism. (A-D) Time evolution of blood glucose concentration, plasma FT4 and TSH concentrations, insulin level, and functional betacellmass. The initial conditions of FT4 and TSH are set to be 12.5 pg/ml and 0.6 mU/l, respectively. The parametervalues are listed in Table 1 . We assume the FT4 synthesis factor for patient A to be a1(t)=6.9+30/(1+e^(6−0.01t)) . Withthe gradual elevation of FT4, the glucose level of this patient would reach 122.5 mg/dl on day 507. The glucose wouldbe dragged down slightly to 114.5 mg/dl in 63 days by improved insulin sensitivity. However, the glucose level wouldrise again thereafter subsequent to the continuous decline of insulin, which is caused by the damage of excessive thyroidhormones to beta-cells. With the gradual elevation of FT4 for 1.7 years, the glucose level of patient A would cross 125mg/dl, the threshold of overt diabetes. As the FT4 level further increases, a complete beta-cell failure occurs and drivespatient A to the late stage of diabetes.CC BY · PubMed Central
Figure 6 Dynamics of glucose, insulin, and functional beta-cell mass level with slowly progressing hyperthyroidism.Here a1(t)=6.9+30/(1+e^(6−t/1300)). All the other parameter values and initial conditions remain the same as in Figure 5. (A-D) Time evolution of blood glucose concentration, plasma FT4 and TSH concentrations, insulin level, and functionalbeta-cell mass. Graph (b) shows patient B would reach the FT4 level of 20 mg/dl in approximately 18.5 years, whichis delayed 17 years than patient A. The time for him to develop diabetes would be postponed for 16.7 years, comparedwith patient A. However, patient B would step into the late stage of diabetes with an FT4 level of 24.1 pg/ml, whilepatient A just cross the threshold of diabetes with the same level of FT4.
Figure 6 Dynamics of glucose, insulin, and functional beta-cell mass level with slowly progressing hyperthyroidism.Here a1(t)=6.9+30/(1+e^(6−t/1300)). All the other parameter values and initial conditions remain the same as in Figure 5. (A-D) Time evolution of blood glucose concentration, plasma FT4 and TSH concentrations, insulin level, and functionalbeta-cell mass. Graph (b) shows patient B would reach the FT4 level of 20 mg/dl in approximately 18.5 years, whichis delayed 17 years than patient A. The time for him to develop diabetes would be postponed for 16.7 years, comparedwith patient A. However, patient B would step into the late stage of diabetes with an FT4 level of 24.1 pg/ml, whilepatient A just cross the threshold of diabetes with the same level of FT4.CC BY · PubMed Central
Figure 7 Dynamics of altered glucose, insulin, and functional beta-cell mass levels with timely treated hyperthyroidism. The ATD dosage D is designed as a piecewise function in the following pattern: D = 0, for t ≤ 500; D = 3, for 500< t ≤ 600; D = 8, for 600< t ≤ 700; D = 12, for 700< t ≤ 800; D = 15, for 800< t ≤ 900; D = 20, for t > 900. The parameter values in the drug intervention term are: d 3 = 1, IC 50 = 30. All the other parameter values and initial conditions remain the same as those in Figure 5 . The initial rise of FT4 level would cause a temporary upsurge of glucose level around the initial point, which is then quickly counterbalanced by the fast increase of insulin levels. In contrast with the increasing trend of the glucose level in Figure fFT4fastProgressingHyper(a), the administration of 3mg ATD drug after day 500 can drag the FT4 level down by 5.2 pg/ml in 10 days, followed by the 19.3 units reduction of glucose level and 19.6 units decrease of insulin level. However, the dose is not enough to prevent the FT4 level from increasing after day 510, which would result in the rise of glucose. We then increase the ATD dose to 5 mg after day 600. As a result, the elevated dosage would drive the FT4 down close to its set point value, and the glucose level would decrease again. Yet this level of treatment is insufficient as the inherent deterioration of the thyroid remains. To enhance the treatment, an increased dosage is applied every one hundred days until day 900 when the dosage becomes fixed. At the end, the FT4 level approaches the steady state with 12.9 pg/ml and the glucose level would be regulated within the normal range after day 1500.
Figure 7 Dynamics of altered glucose, insulin, and functional beta-cell mass levels with timely treated hyperthyroidism. The ATD dosage D is designed as a piecewise function in the following pattern: D = 0, for t ≤ 500; D = 3, for 500< t ≤ 600; D = 8, for 600< t ≤ 700; D = 12, for 700< t ≤ 800; D = 15, for 800< t ≤ 900; D = 20, for t > 900. The parameter values in the drug intervention term are: d 3 = 1, IC 50 = 30. All the other parameter values and initial conditions remain the same as those in Figure 5 . The initial rise of FT4 level would cause a temporary upsurge of glucose level around the initial point, which is then quickly counterbalanced by the fast increase of insulin levels. In contrast with the increasing trend of the glucose level in Figure fFT4fastProgressingHyper(a), the administration of 3mg ATD drug after day 500 can drag the FT4 level down by 5.2 pg/ml in 10 days, followed by the 19.3 units reduction of glucose level and 19.6 units decrease of insulin level. However, the dose is not enough to prevent the FT4 level from increasing after day 510, which would result in the rise of glucose. We then increase the ATD dose to 5 mg after day 600. As a result, the elevated dosage would drive the FT4 down close to its set point value, and the glucose level would decrease again. Yet this level of treatment is insufficient as the inherent deterioration of the thyroid remains. To enhance the treatment, an increased dosage is applied every one hundred days until day 900 when the dosage becomes fixed. At the end, the FT4 level approaches the steady state with 12.9 pg/ml and the glucose level would be regulated within the normal range after day 1500.CC BY · PubMed Central
Figure 8 Dynamics of altered glucose, insulin, and functional beta-cell mass levels with belatedly treated hyperthyroidism. The ATD dosage D is designed as a piecewise function in the following pattern: D = 0, for t ≤ 700; D = 12, for 700< t ≤ 800; D = 15, for 800< t ≤ 900; D = 20, for t > 900. All the other parameter values and initial conditions remain the same as those in Figure 7 . The anti-hyperthyroid treatment starts at day 700, when the beta-cell defect already occurred. Although the FT4 level sharply decreases and approaches the set point value after day 1000, there is no apparent mitigation of diabetes, which is in significant contrast with the outcome of timely treated hyperthyroidism.
Figure 8 Dynamics of altered glucose, insulin, and functional beta-cell mass levels with belatedly treated hyperthyroidism. The ATD dosage D is designed as a piecewise function in the following pattern: D = 0, for t ≤ 700; D = 12, for 700< t ≤ 800; D = 15, for 800< t ≤ 900; D = 20, for t > 900. All the other parameter values and initial conditions remain the same as those in Figure 7 . The anti-hyperthyroid treatment starts at day 700, when the beta-cell defect already occurred. Although the FT4 level sharply decreases and approaches the set point value after day 1000, there is no apparent mitigation of diabetes, which is in significant contrast with the outcome of timely treated hyperthyroidism.CC BY · PubMed Central

Verification

Claims the paper makes

40 Valid · 1 Not valid · 36 Not checked · 60 Own results and interpretations

88 more claims · 16 with their cited sources checked

Create a free account to see all 137 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 26

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 84 references

Research works printed but not linked: 4

  1. Chwalba, 2020, Secondary diabetes, Austin J Nutr Metab, 1077
  2. Hall, 2010, Guyton and hall textbook of medical physiology e-book
  3. Ahren, 2003, Beta-cell function and insulin secretion
  4. Genuth, 1990, Associations between diabetes and other endocrine disorders, Clin Diabetes

Cited by

See all 6

Metadata

Authors
Yang, B., Li, J., Haller, M. J., Schatz, D. A., & Rong, L.
Affiliations
  • University of Florida (US)
  • University of Louisville (US)
Corresponding author
Rong, Libin
Venue
Frontiers in Endocrinology
Published
2022-12-21
Volume
13
Pages
1070979-1070979
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4313484162
Cited by
6
References
84
Citations by year
2025: 3 · 2024: 2 · 2023: 1
FWCI
0.36
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Science Foundation (1950254)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
secondary diabetes, diabetes progression, hyperthyroidism, glucocorticoid-induced diabetes, epinephrine, growth hormone, beta-cell failure, hyperglycemia, thyroid treatment
MeSH terms
Diabetes Mellitus, Type 2, Endocrine System Diseases, Endocrine System, Glucose, Humans, Hyperglycemia, Hyperthyroidism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The progression of secondary diabetes: A review of modeling studies. https://app.cochat.ai/papers/10.3389/fendo.2022.1070979
The paper
Yang, B., Li, J., Haller, M. J., Schatz, D. A., & Rong, L. (2022). The progression of secondary diabetes: A review of modeling studies. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1070979

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.